Liminatus Pharma, Inc.
LIMN
$0.98
$0.077.39%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 701.20K | 1.12M | -- | 167.00K | 186.10K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | 300.00 | -- | -- |
| Total Operating Expenses | 701.20K | 1.12M | 300.00 | 167.00K | 543.10K |
| Operating Income | -701.20K | -1.12M | -300.00 | -167.00K | -543.10K |
| Income Before Tax | -1.82M | 113.30K | -300.00 | -229.00K | -601.40K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.82M | 113.30K | -300.00 | -229.00K | -601.40K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.82M | 113.30K | -300.00 | -229.00K | -601.40K |
| EBIT | -701.20K | -1.12M | -300.00 | -167.00K | -543.10K |
| EBITDA | -700.60K | -1.12M | -- | -- | -- |
| EPS Basic | -0.07 | 0.00 | 0.00 | 0.00 | -0.03 |
| Normalized Basic EPS | -0.06 | -0.03 | 0.00 | 0.00 | -0.02 |
| EPS Diluted | -0.07 | 0.00 | 0.00 | 0.00 | -0.03 |
| Normalized Diluted EPS | -0.06 | -0.03 | 0.00 | 0.00 | -0.02 |
| Average Basic Shares Outstanding | 27.01M | 23.30M | 26.01M | 112.22M | 17.50M |
| Average Diluted Shares Outstanding | 27.01M | 23.30M | 26.01M | 112.22M | 17.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |